Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test® with Anavex Life Sciences Corp.
Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 – Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases
Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model.
Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor
